Table 1.

Resume of published clinical trials.

	Authors	N=	Transplant Type	Scaffold	Delivery Technique	Adverse Events	BCVA Improvement (ETDRS)
DRY AMD	Schwartz et al.	9	hESC-derived suspension	n/a	Subretinal injection (38G) after vitrectomy	1 vitreous inflammation 1 mild ERM 1 cataract	15 letters in 4 eyes 11–14 letters in 3 eyes <10 letters in 3 eyes
	Riemann et al. (poster)	16 (4 different cohorts)	hESC-derived RPE cells suspension	n/a	-PPV retinotomy -Orbit subretinal delivery system (SDS)	PPV group 2 severe ERM SDS group eyelid edema and subconjunctival hemorrhage	10–22 letters (cohort 4 n = 4)
	Kashani et al.	5	hESC-derived RPE monolayers 3.5 mm × 6.25 mm	Parylene C	PPV and retinotomy		17 letters in 1 patient, none in the other 3
WET AMD	Tezel et al.	12	adult human allogeneic RPE cells	n/a	PPV and subfoveal membranectomy with transplantation	6 graft fibrosis, 3 retinal detachments with PVR, 2 ERM, 1 graft migration	No change
	Binder et al.	53 (39 transplanted, 14 controls)	Autologous RPE cellular suspension	n/a	PPV and subretinal injection	None	Better reading acuity and higher mfERG-response density than control subjects
	Mandai et al.	1	autologous (iPSC) from skin fibroblasts 1.3 mm × 3 mm	no	PPV, membranectomy and patch implant		No change
	Da Cruz et al.	2 with subretinal hemorrhage	hESC 6 mm × 3 mm	PET		1 retinal detachment	29 and 21 letters
	Sugita et al.	5	HLA homozygote iPS cellular suspension		Subretinal injection (38G) after vitrectomy	2 mild rejections 1 ERM	No change
STGD1	Schwartz et al.	9	hESC-derived RPE cells suspension		Subretinal injection after vitrectomy	3 cataracts 1 vitreous inflammation	At 6 months: At least 15 letters in 3 eyes, stable in 4 eyes and 1 eye lost 11 letters. At 12 months: At least 15 letters in 3 patients, stable in 3 patients, and 1 had a decrease of more than 10 letters.
	Mehat et al.	12	hESC line MA09-derived RPE cellular suspension		Subretinal injection (38G) after vitrectomy	5 immunosuppression related events. 1nonpigmented and noncontractile epiretinal membrane. 2 visual floaters.	No change
	Li et al.	7	hESC-derived RPE cells suspension		-PPV -injection of saline solution (41G) to detach the temporal retina. -cellular into the macular sub-retinal space.	2 transient increases in intraocular pressure (26–32 mmHg).	At 1–4 months: 7 eyes had transiently increased or stable visual function At the last follow-up visit: visual function loss in 2 eyes (1 of them stable when compared to the fellow eye).
	Sung et al.	3	hESC-derived RPE cells suspension		Subretinal injection after vitrectomy		1 eye showed improvement, 1 eye showed stability

PPV: pars plana vitrectomy, ERM: epiretinal membrane.